Risk factors for severe immune‐related pneumonitis after nivolumab plus ipilimumab therapy for non‐small cell lung cancer
Toshiyuki Sumi,Motoki Sekikawa,Yuta Koshino,Daiki Nagayama,Yuta Nagahisa,Keigo Matsuura,Naoki Shijubou,Koki Kamada,Keito Suzuki,Takumi Ikeda,Haruhiko Michimata,Hiroki Watanabe,Yuichi Yamada,Koichi Osuda,Yusuke Tanaka,Hirofumi Chiba
DOI: https://doi.org/10.1111/1759-7714.15385
IF: 3.223
2024-06-05
Thoracic Cancer
Abstract:We investigated the relationship between tumor burden and the risk of severe pneumonitis in patients with non‐small cell lung cancer (NSCLC) treated with ipilimumab and nivolumab. The study, conducted from December 2020 to December 2022 with 76 NSCLC patients, evaluated various factors including age, sex, smoking status, PD‐L1 expression, tumor size, presence of fibrosis, serum markers, and respiratory function tests. The results indicate that lower diffusing capacity for carbon monoxide (%DLCO), higher surfactant protein D (SP‐D) levels, and the presence of squamous cell carcinoma along with fibrosis significantly increase the risk of severe pneumonitis, with respective odds ratios indicating substantial increases in risk. Additionally, the study found that in patients without pre‐existing fibrosis, an increase in tumor burden correlated significantly with the incidence of severe pneumonitis. These findings emphasize the need for careful monitoring and proactive interventions in at‐risk patients, illustrating the critical influence of tumor characteristics and treatment modalities on patient outcomes in NSCLC therapy. Background The efficacy of anti‐CTLA‐4 antibody (ipilimumab) plus anti‐programmed cell death 1 antibody (nivolumab) in treating advanced non‐small cell lung cancer (NSCLC) is impeded by an elevated risk of severe immune‐related adverse events. However, our understanding of associations among pre‐existing fibrosis, emphysematous changes, and objective indicators as predictive factors is limited for severe pneumonitis in NSCLC patients receiving this combination therapy. Thus, we retrospectively investigated these associations, including overall tumor burden, before treatment initiation in the Japanese population. Methods We focused on patients (n = 76) with pre‐existing interstitial lung disease (ILD) to identify predictors of severe pneumonitis. Variables included age, sex, smoking status, programmed cell death ligand 1 expression, overall tumor burden, chest computed tomography‐confirmed fibrosis, serum markers, and respiratory function test results. Results Severe pneumonitis was more frequent in patients with squamous cell carcinoma, fibrosis, low diffusing capacity for carbon monoxide (%DLCO), and high surfactant protein D (SP‐D) level. Notably, squamous cell carcinoma, baseline %DLCO, and SP‐D level were significant risk factors. Our findings revealed the nonsignificance of tumor burden (≥85 mm) in predicting severe pneumonitis, emphasizing the importance of pre‐existing ILD. Conversely, in cases without pre‐existing fibrosis, severe pneumonitis was not associated with %DLCO or SP‐D level (93.2% vs. 91.9%, and 63.3 vs. 40.9 ng/mL, respectively) and was more common in patients with a large overall tumor burden (97.5 vs. 70.0 mm). Conclusion Vigilant monitoring and early intervention are crucial for patients with squamous cell carcinoma, high SP‐D level, or low %DLCO undergoing ipilimumab plus nivolumab therapy.
oncology,respiratory system